Mission statement: 

At OCCR, our goal is to offer our patients the very best in medical treatment. We care about and respect the patients who make progress in clinical research possible, and it is our mission to enhance their quality of life. Our Research department is actively engaged in developing our own independent research as well as finding the latest and the very best clinical trials to offer our patients.

Recruiting Studies

We are accepting eligible participants for the studies below: 

Glaucoma – View flyer

Recruiting patients with glaucoma or high eye pressure for a new investigational eye drop research study

• Principal Investigators and study sites: Dr. Jivanjee in Troy, Dr. Madiwale in Clifton Park

Macular degeneration study

A prospective, observational, post-marketing surveillance study to monitor the safety of the port delivery system in patients with Neovascular (wet) Age-Related Macular Degeneration (VILLA Study)

• Principal Investigator: Robert Feldman, MD
• Study sites: Troy, Clifton Park, Schenectady, Albany, Schodack

Macular degeneration study

Epidemiological Study of the progression of Age-related Macular Degeneration (AMD)

• Study site: All offices

Macular degeneration studies

A Phase I, Multicenter, Open-Label, Single- and Multi-Dose, Dose-Escalating Clinical Study to Evaluate the Safety and Tolerability of OLX10212 Administered by Intravitreal Injection in Patients With Neovascular Age-Related Macular Degeneration

• Principal Investigator: Dr. Robert Feldman
• Study Site: Troy

If you are interested in participating or want more information please call our Research team at 518-274-3123 extension 127.

Completed Studies

A RANDOMIZED, DOUBLE-MASKED, PHASE 3 STUDY OF ABP 938 EFFICACY AND SAFETY COMPARED TO AFLIBERCEPT (EYLEA) IN SUBJECTS WITH NEOVASCULAR AGE RELATED MACULAR DEGENERATION

A PHASE 2 MULTICENTER, RANDOMIZED, DOUBLE-MASKED, SHAM-CONTROLLED STUDY OF THE SAFETY AND EFFICACY OF INTRAVITREAL INJECTIONS OF NGM621 IN SUBJECTS WITH GEOGRAPHIC ATROPHY (GA) SECONDARY TO AGE-RELATED MACULAR DEGENERATION (AMD) (CATALINA)

DEXTENZA VS PREDNISOLONE ACETATE 1% IN THE INCIDENCE OF PSEUDOPHAKIC MACULAR EDEMA IN PATIENTS WITH DIABETIC RETINOPATHY UNDERGOING CATARACT SURGERY – REDUCE STUDY

A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA

A PHASE 3 MULTICENTER, RANDOMIZED, DOUBLE-MASKED, SHAM-CONTROLLED CLINICAL TRIAL TO ASSESS THE SAFETY AND EFFICACY OF INTRAVITREAL ADMINISTRATION OF ZIMURA (COMPLIMENT C5 INHIBITOR) IN PATIENTS WITH GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION

RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED, PHASE 3 STUDY OF THE EFFICACY AND SAFETY OF HIGH DOSE AFLIBERCEPT IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION